As part of the partnership, PPC will use the Patient Network Explorer platform to advance clinical trials, trial enrollment, and accelerate global studies conducted in the People’s Republic of China, the Republic of China (Taiwan) and the Republic of Korea (South Korea). PPC will encourage hospitals to participate in Clinerion’s Patient Network Explorer platform for generation of RWD/RWE and bringing more global studies to hospitals.
PPC provides a fully integrated solution for Phase I-IV studies in Asian countries. PPC is dedicated to serve the pharmaceutical and biotechnology industry with world-class quality and cost-effective solutions to shorten the lead time to market. PPC provides full services for clinical trials, such as Project Management, Regulatory Affairs, Clinical Monitoring, Biostatistics, Data Management, Medical Writing, and Pharmacovigilance.
Patient Network Explorer supports patient health by matching patients from Clinerion’s global network of hospitals to clinical trials conducted by pharmaceutical sponsors or researchers performing academic investigations. The system is based on de-identified EHR data, unlinked from any identifiers, protecting patient privacy. The partners’ combined services will accelerate access for patients and hospitals to next-generation medical treatments. Patients in the region will become more visible to sponsors for trial recruitment, and hospitals in the region will become better placed to run clinical trials, ultimately accelerating drug launch.
“We are excited to be partnering with Clinerion to jointly offer our customers access to global integrated recruitment services through the Patient Network Explorer platform,” says Michael Stibilj, CEO of PPC. “This relationship will enable researchers and hospitals, in our region, to have additional opportunities to be involved in global trials, also providing patients access to new potential treatments. Increased access to patients will speed up the clinical trial process and help accelerate the development of break-through products.”
“The strength of Patient Network Explorer lies in its global coverage,” says Ian Rentsch, Clinerion CEO. “Clinerion’s hospital network currently covers 19 countries and over 73 M patients. The partnership with PPC promises to deepen our presence in Korea and Taiwan, and expand our coverage to China. Clinerion continues to build our global presence!”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.